These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19639292)

  • 41. Adenosine and related drugs in brain diseases: present and future in clinical trials.
    Lopes LV; Sebastião AM; Ribeiro JA
    Curr Top Med Chem; 2011; 11(8):1087-101. PubMed ID: 21401493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adenosine Receptors in Modulation of Central Nervous System Disorders.
    Choudhury H; Chellappan DK; Sengupta P; Pandey M; Gorain B
    Curr Pharm Des; 2019; 25(26):2808-2827. PubMed ID: 31309883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling.
    Nishi A; Liu F; Matsuyama S; Hamada M; Higashi H; Nairn AC; Greengard P
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1322-7. PubMed ID: 12538871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction between A1 adenosine and class II metabotropic glutamate receptors in the regulation of purine and glutamate release from rat hippocampal slices.
    Di Iorio P; Battaglia G; Ciccarelli R; Ballerini P; Giuliani P; Poli A; Nicoletti F; Caciagli F
    J Neurochem; 1996 Jul; 67(1):302-9. PubMed ID: 8667006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role and regulation of adenosine in the central nervous system.
    Dunwiddie TV; Masino SA
    Annu Rev Neurosci; 2001; 24():31-55. PubMed ID: 11283304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies.
    Wei CJ; Li W; Chen JF
    Biochim Biophys Acta; 2011 May; 1808(5):1358-79. PubMed ID: 21185258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fine-tuning neuromodulation by adenosine.
    Sebastião AM; Ribeiro JA
    Trends Pharmacol Sci; 2000 Sep; 21(9):341-6. PubMed ID: 10973087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuromodulation and metamodulation by adenosine: Impact and subtleties upon synaptic plasticity regulation.
    Sebastião AM; Ribeiro JA
    Brain Res; 2015 Sep; 1621():102-13. PubMed ID: 25446444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Purinergic inhibition of neurotransmitter release in the central nervous system.
    Ribeiro JA
    Pharmacol Toxicol; 1995 Nov; 77(5):299-305. PubMed ID: 8778740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.
    Fuxe K; Marcellino D; Borroto-Escuela DO; Guescini M; Fernández-Dueñas V; Tanganelli S; Rivera A; Ciruela F; Agnati LF
    CNS Neurosci Ther; 2010 Jun; 16(3):e18-42. PubMed ID: 20345970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adenosine A2A receptors and neuroprotection.
    Ongini E; Adami M; Ferri C; Bertorelli R
    Ann N Y Acad Sci; 1997 Oct; 825():30-48. PubMed ID: 9369973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of adenosine in the regulation of sleep.
    Huang ZL; Urade Y; Hayaishi O
    Curr Top Med Chem; 2011; 11(8):1047-57. PubMed ID: 21401496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenosine A2A receptors and Parkinson's disease.
    Morelli M; Carta AR; Jenner P
    Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signaling by adenosine receptors-Homeostatic or allostatic control?
    Cunha RA
    PLoS Biol; 2019 Apr; 17(4):e3000213. PubMed ID: 30951527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors.
    Ozola V; Thorand M; Diekmann M; Qurishi R; Schumacher B; Jacobson KA; Müller CE
    Bioorg Med Chem; 2003 Feb; 11(3):347-56. PubMed ID: 12517430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adenosine Receptors as Novel Targets for the Treatment of Various Cancers.
    Gorain B; Choudhury H; Yee GS; Bhattamisra SK
    Curr Pharm Des; 2019; 25(26):2828-2841. PubMed ID: 31333092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum.
    Rodrigues RJ; Alfaro TM; Rebola N; Oliveira CR; Cunha RA
    J Neurochem; 2005 Feb; 92(3):433-41. PubMed ID: 15659214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats.
    Rebola N; Sebastião AM; de Mendonca A; Oliveira CR; Ribeiro JA; Cunha RA
    J Neurophysiol; 2003 Aug; 90(2):1295-303. PubMed ID: 12904509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.
    Deb PK; Deka S; Borah P; Abed SN; Klotz KN
    Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.